Perspective Therapeutics (CATX) said Tuesday the European Commission granted orphan medicinal product designation to its experimental therapy for the treatment of gastroenteropancreatic neuroendocrine tumors, following a positive recommendation from the European Medicines Agency's Committee for Orphan Medicinal Products.
The company said the designation provides development and potential commercial incentives, including protocol assistance, fee reductions and, if approved, up to 10 years of market exclusivity in the European Union.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments